Initial Treatment for Hypertrophic Obstructive Cardiomyopathy (HOCM)

First-Line Therapy: Beta-Blockers

The American College of Cardiology recommends beta-blockers as the first-line treatment for symptomatic HOCM, titrated to achieve a resting heart rate below 60-65 bpm, as they reduce left ventricular outflow tract obstruction through negative inotropic and chronotropic effects 1, 2
Non-vasodilating beta-blockers, such as metoprolol, propranolol, or atenolol, should be initiated and titrated to maximum tolerated doses, targeting a resting heart rate of less than 60-65 bpm 1, 2, 3
Beta-blockers work by slowing heart rate, improving diastolic filling time, reducing myocardial oxygen demand, and decreasing the dynamic outflow tract gradient 4
Dosing should be pushed until physiologic beta-blockade is achieved (demonstrated by resting heart rate suppression) before declaring treatment failure 1

If beta-blockers are ineffective, not tolerated, or contraindicated, verapamil or diltiazem are reasonable alternatives 1, 2
Verapamil should be started at low doses and titrated up to 480 mg/day, providing relief through negative inotropic and chronotropic effects 2, 3
Verapamil should be used with extreme caution in patients with high gradients or advanced heart failure symptoms 3
Never combine beta-blockers with verapamil or diltiazem due to risk of high-grade atrioventricular block 3, 4

The American College of Cardiology recommends discontinuing all vasodilators, including dihydropyridine calcium channel blockers, ACE inhibitors, and ARBs, as they worsen outflow tract obstruction 1, 2, 3
Avoid high-dose diuretics that may promote obstruction through volume depletion; low-dose diuretics may be cautiously added only if congestive symptoms persist despite first-line therapy 1, 2
Digitalis is potentially harmful in HOCM patients without atrial fibrillation 3, 4

If symptoms persist despite optimal first-line therapy, add disopyramide (400-600 mg/day) combined with beta-blocker or verapamil—never as monotherapy due to risk of enhanced AV conduction in atrial fibrillation 1, 2, 3
Consider mavacamten (cardiac myosin inhibitor) in adults, which improves gradients and symptoms in 30-60% of patients, though 7-10% may develop reversible LVEF reduction <50% requiring temporary discontinuation 1
Septal reduction therapy (surgical myectomy or alcohol septal ablation) for severely symptomatic patients despite optimal medical therapy, performed only at experienced comprehensive HCM centers 1, 2

Do not declare beta-blocker failure until adequate dosing achieves resting heart rate suppression (physiologic evidence of beta-blockade) 1
Never use combination beta-blocker plus calcium channel blocker for HOCM treatment due to AV block risk, though this combination may have a role in managing concomitant hypertension 1, 3
Avoid septal reduction therapy in asymptomatic patients regardless of gradient severity, as there is no benefit and potential harm 2, 3
Success is determined by symptom response, not measured gradient, as outflow tract obstruction varies remarkably throughout daily life 1

For atrial fibrillation/flutter, initiate anticoagulation immediately regardless of CHA₂DS₂-VASc score, as all HOCM patients with AF require anticoagulation 2, 3